Journal of Cosmetic Dermatology最新文献

{"title":"A Critical Narrative Review and Expert Consensus on the Clinical Positioning of Non-Ablative Laser-Based Therapy in Acne Treatment","authors":"Fabienne Ballanger,&nbsp;Marie-Thérèse Leccia,&nbsp;Nicole Auffret,&nbsp;Jean-Paul Claudel,&nbsp;Brigitte Dréno","doi":"10.1111/jocd.71218","DOIUrl":"https://doi.org/10.1111/jocd.71218","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Acne is characterized by inflammatory and non-inflammatory lesions. Traditional therapies include topical and systemic agents, which often face limitations such as resistance and side effects. Non-ablative laser-based therapy (LBT) has emerged as a promising modality, offering targeted effects on sebaceous glands and <i>Cutibacterium acnes</i>.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This work discusses the mechanisms, clinical applications, efficacy, limitations, and future directions of laser therapy in active acne lesion management, excluding scars and post-inflammatory hyperpigmentation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>Five experts in acne analyzed the content of 15 published sources between 2004 and 2025 and propose an acne treatment approach that includes the use of non-ablative LBT.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Limited clinical evidence suggests that non-ablative LBT provides safe and effective reduction of lesions. However, variability in protocols, limited clinical evidence, and accessibility do not allow confirmation of non-ablative LBT as a valuable treatment alternative to conventional treatment. Non-ablative LBT may be safe and effective as an alternative to first-line intention medication in mild acne and as an adjuvant second-line treatment to conventional treatment or if conventional second-line acne treatment fails. Efficacy remains to be confirmed through well-designed and sufficiently powered clinical studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Non-ablative LBT may be a useful and effective future option for acne management, offering both lesion clearance and cosmetic improvement. Proper protocol selection and validated clinical investigations in large cohorts that allow for a critical assessment of the different available non-ablative LBT approaches remain mandatory to objectively confirm its clinical benefit in the treatment of active acne lesions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71218","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Burden of Acne (1990–2021) and Projections for China's Disease Burden Over the Next 15 Years: A Comprehensive Study Based on Global Burden of Disease Data","authors":"Qian Zhang,&nbsp;Peixuan Wu,&nbsp;Chun Yang,&nbsp;Zijie He,&nbsp;Yanyan Feng","doi":"10.1111/jocd.71118","DOIUrl":"https://doi.org/10.1111/jocd.71118","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Acne vulgaris is a common chronic inflammatory skin disease with a significant impact on the global health burden. Although acne vulgaris is more prevalent among adolescents, the incidence of adult acne is gradually increasing, imposing a severe psychological and social burden, particularly on women of reproductive age. China accounts for 18% of the global population, yet previous GBD studies have paid insufficient attention to the evolving burden of acne in the country. With China's Socio-demographic Index (SDI) rising rapidly, it serves as an ideal case for examining the relationship between socioeconomic transition and disease burden. This study aims to analyze trends in the global burden of acne vulgaris from 1990 to 2021, examine regional, national, age, and gender disparities, assess associations with sociodemographic indicators, and project future trends in China's acne vulgaris burden over the next 15 years. Prior studies have largely been confined to single continents or specific countries, with data typically limited to 2017 or earlier. In contrast, this study spans 204 countries and territories worldwide from 1990 to 2021, significantly expanding both temporal and spatial coverage. It is the first to systematically delineate nonlinear associations within the Socio-demographic Index (SDI) framework, revealing a distinctive epidemiological curve characterized by an initial decline followed by a subsequent rise. Furthermore, by incorporating projections of China's disease burden over the next 15 years, this research provides robust empirical evidence to inform public health policymaking across the Asia-Pacific region.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Using the Global Burden of Disease (GBD) 2021 database, we extracted data on acne vulgaris incidence, prevalence, disability-adjusted life years (DALYs), and age-standardized rates from 204 countries and regions worldwide between 1990 and 2021. Trend analysis employed age-standardized rates, estimated annual percentage change (EAPC), and Bayesian modeling, with socioeconomic factors assessed using the Socio-Demographic Index (SDI).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In 2021, 239.7 million prevalent cases and 124.3 million incident cases of acne vulgaris were reported globally, accounting for 5.126 million DALYs. The global age-standardized prevalence, incidence, and DALY rates for acne vulgaris were 3142.5 per 100 000 population (95% uncertainty interval: 2867.0 to 3500.6), 1645.2 (1459.7 to 1878.2), and 67.2 (42.3 to 105.8) per 100 000 population, representing increases of 12.2%, 14%, and 12.3% compared to 1990. In 2021, Germany (","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71118","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adapalene-Associated Cutaneous Adverse Events: A Disproportionality Analysis of the FAERS Database","authors":"Zhongping Cao,&nbsp;Chenyu Zhao","doi":"10.1111/jocd.71207","DOIUrl":"https://doi.org/10.1111/jocd.71207","url":null,"abstract":"&lt;p&gt;Adapalene is a third-generation topical retinoid which is highly effective, generally well-tolerated first-line topical treatment for acne [&lt;span&gt;1, 2&lt;/span&gt;]. Its expected local effects, including dryness, erythema, burning, scaling, and irritation, are familiar to dermatologists. However, spontaneous-reporting data may capture a wider spectrum of cutaneous terms, including events that overlap with the treated disease or are not explicitly represented in product labeling. We therefore characterized adapalene-associated cutaneous reporting patterns and distinguished expected reactions from indication-related terms and potentially under-recognized signals.&lt;/p&gt;&lt;p&gt;FAERS quarterly files from Q1 2004 through Q4 2025 were analyzed. Reports were included when adapalene was designated the primary suspect drug; ingredient-level standardization included adapalene-containing fixed combinations. Duplicate case versions were removed by retaining the record with the latest FDA receipt date for each CASEID and, when dates were tied, the highest PRIMARYID (Figure 1). Events were coded at the system organ class (SOC) and preferred term (PT) levels using MedDRA version 26.1. Four complementary disproportionality approaches were applied: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network information component (IC), and multi-item gamma Poisson shrinker empirical Bayes geometric mean (EBGM). A drug-PT pair was considered a signal only when all prespecified criteria were met: at least three reports, lower 95% confidence bounds for ROR and PRR greater than 1, IC025 greater than 0, and EBGM05 greater than 2 (Table S1). Counts refer to drug-event records rather than unique patients; one case may contribute multiple PTs.&lt;/p&gt;&lt;p&gt;Skin and subcutaneous tissue disorders accounted for 301 587 records, 70.4% of all adapalene-associated AE records, and showed the strongest SOC-level disproportionality (Table S2). Twenty-two cutaneous PTs satisfied the intersection rule. Skin burning sensation had the highest ROR (234.88; 95% CI, 231.23–238.59), closely followed by skin fragility (232.72; 214.08–252.99). The most frequently reported PTs were dry skin (&lt;i&gt;n&lt;/i&gt; = 46 237), skin burning sensation (&lt;i&gt;n&lt;/i&gt; = 42 445), acne (&lt;i&gt;n&lt;/i&gt; = 40 194), erythema (&lt;i&gt;n&lt;/i&gt; = 39 137), skin irritation (&lt;i&gt;n&lt;/i&gt; = 26 625), and skin exfoliation (&lt;i&gt;n&lt;/i&gt; = 21 980) (Table S3). Signal magnitude alone did not determine clinical interpretation.&lt;/p&gt;&lt;p&gt;Each PT was compared with a frozen U.S. labeling corpus anchored to the December 31, 2025 data cutoff. Adapalene-only prescribing information and OTC Drug Facts were the primary sources; adapalene/benzoyl peroxide labels provided supportive evidence because fixed combinations were retained. Thirteen PTs were classified as labeled/expected, including burning, irritation, pain, dryness, discoloration, discomfort, exfoliation, erythema, rash, dermatitis, and warmth (Table 1). Acne and acne cystic ","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71207","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucuronyl Glucosyloleanolate: A Safe and Potent AI-Discovered Depigmenting Saponin","authors":"Yannick Quesnel,&nbsp;Michael Gold","doi":"10.1111/jocd.71210","DOIUrl":"https://doi.org/10.1111/jocd.71210","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Purpose&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Saponins are amphiphilic glycosides found in plants. They have long been used in traditional Asian remedies for their anti-inflammatory, protective, and rejuvenating properties. One representative, Glucuronyl Glucosyloleanolate (GGO), was recently discovered using a combination of artificial intelligence and experimental testing as a depigmenting agent. Its safety has been verified in humans during a patch test on 12 volunteers, followed by an HRIPT study on 100 volunteers. Finally, its depigmenting efficacy has been demonstrated after a clinical trial on 60 volunteers.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;div&gt;\u0000 \u0000 &lt;ul&gt;\u0000 \u0000 \u0000 &lt;li&gt;A 48-h patch test was conducted on 12 volunteers using the pure compound.&lt;/li&gt;\u0000 \u0000 \u0000 &lt;li&gt;HRIPT: a patch with 0.1% GGO in mineral oil was applied to 100 volunteers repeatedly over 3 weeks. After a 2-week rest, a single patch was applied again to the induction site and to a new, untreated site for the challenge phase.&lt;/li&gt;\u0000 \u0000 \u0000 &lt;li&gt;Clinical trial: monocentric blind study of GGO (0.01% weight) versus placebo on a multi-ethnic panel with pigmentation spots.&lt;/li&gt;\u0000 &lt;/ul&gt;\u0000 &lt;/div&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;div&gt;\u0000 \u0000 &lt;ul&gt;\u0000 \u0000 \u0000 &lt;li&gt;Safety: No skin irritation or adverse effects were observed in the patch test assay confirming the product's excellent safety. On the 100 volunteers, during the induction period, no reaction of irritation was observed after 3 weeks and during the challenge phase, no allergic reaction was observed. Based on these results, GGO demonstrated very good skin compatibility and does not show a sensitizing effect.&lt;/li&gt;\u0000 \u0000 \u0000 &lt;li&gt;Efficacy: all subgroups showed significant depigmentation from Day 21 onwards, which continued to increase in a similar manner to that observed with localized depigmentation. After 84 days, the level of depigmentation achieved was 10% on Asian, 14% on Caucasian and North African skin, and 24% on black skin. Dark Pigmentation spots on Asian and Caucasian skin depigmented at a rate 34% faster than the overall skin tone, resulting in their visual fading&lt;/li&gt;\u0000 &lt;/ul&gt;\u0000 &lt;/div&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 ","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71210","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Featured Cover","authors":"","doi":"10.1111/jocd.71212","DOIUrl":"https://doi.org/10.1111/jocd.71212","url":null,"abstract":"<p>The cover image is based on the article <i>Reviving the Skin From Within: Mechanistic Insights Into a Well-Tolerated Dermal Filler—CPM-HA20G</i> by Kay Marquardt et al., https://doi.org/10.1111/jocd.70996.\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </p>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71212","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Efficacy and Mechanisms of ZiyuShuang, an Anti-Skin Aging Formula Identified Through Network Medicine Framework Analysis","authors":"Yingpeng Tong,&nbsp;Xiangmei Ni,&nbsp;Xinnan Jiang,&nbsp;Ru Zhang,&nbsp;Pengcheng Guo,&nbsp;Chunbo Feng,&nbsp;Jianxin Wang","doi":"10.1111/jocd.71171","DOIUrl":"https://doi.org/10.1111/jocd.71171","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Skin aging, a key aspect of physiological decline, markedly affects appearance, making strategies to delay it vital for quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>We applied network medicine analysis to screen herbal medicines from the TCMSP database, yielding an anti-skin aging formula, ZiYuShuang (ZYS). Its efficacy and mechanisms were evaluated using network pharmacology, in vitro assays, and clinical trials.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 155 herbal medicines identified with anti-skin aging potential from TCMSP, Qi-reinforcing drugs were most effective. Informed by literature and preliminary data, we developed ZYS. Network pharmacology linked ZYS's effects to Focal Adhesion, Relaxin Signaling, PI3K-Akt, TNF, and Apoptosis pathways. In vitro, ZYS regulated elastin, collagen (types I, III, IV, VII), and decorin expression. Clinically, ZYS enhanced skin hydration, glossiness, transparency, dermal density, and thickness, while reducing redness, yellowness, firmness, roughness, and wrinkle severity (forehead lines, nasolabial folds, crow's feet, and total facial lines).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>ZYS, derived from network medicine, emerges as a potent adjunct for skin aging interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71171","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Interactions Unique to Intradermal Microtoxin: Insights From Aesthetic, Therapeutic, and Vaccination Studies","authors":"Je-Young Park,&nbsp;Luis Alberto Parra Hernandez,&nbsp;Hossam Elenany,&nbsp;Martina Kerscher,&nbsp;William Gregory Chernoff,&nbsp;Warner Carr,&nbsp;Samantha Tran","doi":"10.1111/jocd.71164","DOIUrl":"https://doi.org/10.1111/jocd.71164","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Intradermal botulinum toxin type A (BoNT-A; microtoxin) has been shown to improve skin texture, superficial rhytides, and sweat/sebaceous activity through neuronal (cholinergic) and non-neuronal pathways. While discussions around immune system interactions for BoNT-A in aesthetic indications exist for intramuscular injection, the high density of antigen-presenting cells in the dermis raises the question of whether a different level of concern is warranted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This narrative review was informed by a PubMed search through 2025 identifying studies on intradermal BoNT-A and immunogenicity using combined/related terms for BoNT-A, intradermal injection, microtoxin, immunogenicity, and skin immunology. Reference lists were screened for additional studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The number of publications on microtoxin has increased markedly since 2024. While the skin is an immunologically active organ, immunogenicity data remain limited for aesthetic intradermal injection. To date, only a single prospective study has examined immune responses to intradermal BoNT-A in aesthetic practice. This study showed higher antibody responses with intradermal versus intramuscular delivery. Like data for intramuscular injection, there is a lack of long-term data on neutralizing antibody (NAb) development; however, in the context of increasing BoNT-A doses for facial treatment and increasing long-term exposure, introduction of BoNT-A into the dermis over a large surface may raise the risk of NAb development.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Microtoxin techniques may heighten immunogenic potential through dermal antigen exposure and frequent retreatment. IncobotulinumtoxinA is free of complexing proteins and has a low antigenic protein burden, which may favor its use for intradermal injection. However, direct long-term comparative evidence for aesthetic intradermal treatments is lacking.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71164","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preparation and Characterization of Azelaic Acid-Loaded Nanofiber Scaffold as Anti-Acne and Depigmenting Care, Fabricated by Electrospinning Method","authors":"Niki Yadegari,&nbsp;Fatemeh Majdi,&nbsp;Nooshafarin Amani,&nbsp;Nasrin Samadi,&nbsp;Farid Abedin Dorkoush,&nbsp;Hamid Akbari Javar","doi":"10.1111/jocd.71202","DOIUrl":"https://doi.org/10.1111/jocd.71202","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Acne vulgaris is a common dermatological concern, and conventional topical azelaic acid formulations may have limitations in skin residence time and tolerability. Polymeric nanofiber scaffolds offer a promising platform for topical drug delivery. This study aimed to develop and characterize chitosan/polyvinyl alcohol (CS/PVA) electrospun nanofibers loaded with azelaic acid for potential use in acne management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Azelaic acid-loaded CS/PVA nanofibers were prepared by electrospinning. Morphology was evaluated by scanning electron microscopy, in vitro drug release was assessed by an immersion method, antibacterial activity against <i>Cutibacterium acnes</i> was determined by disk diffusion, and physicochemical stability was examined under accelerated conditions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Nanofibers containing 9% PVA, 2% chitosan, and 50 or 70% azelaic acid showed uniform, bead-free morphology and suitable physical and mechanical properties under optimized electrospinning conditions. The azelaic acid-loaded scaffolds exhibited antimicrobial activity against <i>C. acnes</i>, acceptable stability, and a sustained release profile, with the 70% formulation releasing over approximately 89% of the drug within 24 h.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Azelaic acid-loaded CS/PVA nanofiber scaffolds demonstrated favorable in vitro physicochemical and antibacterial properties as topical delivery systems. The 70% azelaic acid formulation was selected as the optimized scaffold for further preclinical investigation, while in vivo and clinical studies are needed to evaluate its therapeutic efficacy and safety.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149047867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Multimodal Imaging Assessment of Tissue Changes Following Poly-L-Lactic Acid Treatment for Midfacial Rejuvenation: An Exploratory Pilot Study","authors":"Reem AL-Attab,&nbsp;Jiajie Li,&nbsp;Chihchieh Lo,&nbsp;Hang Wang,&nbsp;Shuo Liu","doi":"10.1111/jocd.71178","DOIUrl":"https://doi.org/10.1111/jocd.71178","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Poly-L-lactic acid (PLLA) is increasingly used as a collagen-stimulating injectable for facial rejuvenation, but longitudinal multimodal characterization of volumetric and tissue remodeling changes after treatment remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To characterize longitudinal changes in midfacial volume, ultrasound-derived dermal remodeling parameters, and skin hydration after individualized PLLA treatment, and to explore the potential associations between administered PLLA amount and observed volumetric changes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Six adults with mild-to-moderate midfacial volume deficiency were enrolled in this prospective exploratory pilot study. Twelve hemifaces were treated with individualized PLLA injections over up to three sessions. Outcomes were assessed at baseline and Days 30, 90, 180, and 360 using 3D stereophotogrammetry, high-frequency ultrasound, Corneometer measurements, standardized photography, and safety evaluation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Exploratory analysis suggested a positive association between administered PLLA amount and observed volumetric changes at certain follow-up time points, with the strongest association observed at Day 90. Mean volumetric increase was greatest at Day 360, whereas ultrasound-derived dermal remodeling parameters and skin hydration peaked at Day 90 and remained elevated relative to baseline through Day 360. No serious treatment-related adverse events were observed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this exploratory cohort, individualized PLLA treatment was associated with longitudinal changes in midfacial volume and sustained alterations in ultrasound-derived parameters related to dermal remodeling over 12 months. The observed association between administered PLLA amount and volumetric changes warrants further investigation in controlled studies to better understand factors contributing to variability in treatment outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71178","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149047894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Dose Oral Versus Topical Minoxidil in Androgenetic Alopecia: A Randomized, Double-Blind, Double-Dummy Controlled Trial","authors":"Muhammad Asad Ejaz Chaudhry,&nbsp;Bushra Muneeb,&nbsp;Safoora Aamir,&nbsp;Zoha Arif Saeed,&nbsp;Sidra Ashraf,&nbsp;Shoaib Ashraf","doi":"10.1111/jocd.71198","DOIUrl":"https://doi.org/10.1111/jocd.71198","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Androgenetic alopecia (AGA) is a prevalent, progressive condition with significant psychosocial impact. Current pharmacological modalities like topical minoxidil and finasteride have limitations. Low-dose oral minoxidil has surfaced as a valid off-label solution, with the practical advantage of once-daily dosing.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To evaluate the efficacy and safety of topical and oral minoxidil in AGA.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In this double-blind, double-dummy randomized controlled trial, 100 patients aged 18–50 years with AGA were randomized to receive either twice-daily topical minoxidil (5% in males, 2% in females) plus a placebo tablet, or once-daily oral minoxidil (2.5 mg in males, 1.25 mg in females) plus a placebo spray for 6 months. The primary outcome was the proportion of patients achieving ≥ +1 improvement in a validated 7-point global photographic scale. Secondary outcomes included patient satisfaction and adverse effects. Data were analyzed using SPSS v26 with &lt;i&gt;p&lt;/i&gt; ≤ 0.05 as significant.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Ninety patients completed 24 weeks of follow-up. Photographic assessment demonstrated that mild-to-excellent improvement (≥ +1) occurred in both the oral (67%) and topical minoxidil (73%) groups (&lt;i&gt;p&lt;/i&gt; = 0.652). Patient-reported satisfaction was high in both groups (topical: 70.5%; oral: 80.4%, &lt;i&gt;p&lt;/i&gt; = 0.332), with a non-significant trend favoring oral minoxidil at the moderate satisfaction threshold (58.7% vs. 38.6%, &lt;i&gt;p&lt;/i&gt; = 0.057). Median improvement scores were comparable between groups for both clinician assessment and patient-reported outcomes. Hypertrichosis was significantly more frequent with oral minoxidil (30% vs. 9%, &lt;i&gt;p&lt;/i&gt; = 0.011), whereas contact dermatitis was exclusive to topical minoxidil (11% vs. 0%, &lt;i&gt;p&lt;/i&gt; = 0.025). No serious adverse events were observed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Both topical and low-dose oral minoxidil demonstrated clinically meaningful improvement in androgenetic alopecia. Despite oral therapy exhibiting a trend toward higher patient satisfaction, this study was not powered to establish non-inferiority or equivalence. The dermatologist-assessed outcomes indicated no significant intergroup differences. Low-dose oral minoxidil may be considered a practical alternative in selected patients, particularly where adherence to topical therapy is","PeriodicalId":15546,"journal":{"name":"Journal of Cosmetic Dermatology","volume":"25 10","pages":""},"PeriodicalIF":3.5,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jocd.71198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149047868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}